Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment

Diana V. Do, Quan D. Nguyen, Afsheen A. Khwaja, Roomasa Channa, Yasir J. Sepah, Raafay Sophie, Gulnar Hafiz, Peter A. Campochiaro

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Objective: To assess the benefit of increased follow-up and treatment with ranibizumab between months 24 and 36 in the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study. Design: Prospective, interventional, multicenter follow-up of a randomized clinical trial. Methods: Patients who agreed to participate between months 24 and 36 (ranibizumab, 28 patients; laser, 22; and ranibizumab + laser, 24) returned monthly and received ranibizumab, 0.5 mg, if foveal thickness (FTH, center subfield thickness) was 250 μm or greater. Main outcome measures were improvement in best-corrected visual acuity (BCVA) and reduction in FTH between months 24 and 36. Results: Mean improvement from the baseline BCVA in the ranibizumab group was 10.3 letters at month 36 vs 7.2 letters at month 24 (ΔBCVA letters = 3.1, P = .009), and FTH at month 36 was 282 μm vs 352 μm at month 24 (ΔFTH=70 μm, P=.006). Changes in BCVA and FTH in the laser group (-1.6 letters and -36 μm, respectively) and the ranibizumab + laser group (+ 2.0 letters and -24 μm) were not statistically significant. The mean number of ranibizumab injections was significantly greater in the ranibizumab group compared with the laser group (5.4 vs 2.3 injections, P = .008) but not compared with the ranibizumab + laser group (3.3, P =.11). Conclusions: More aggressive treatment with ranibizumab during year 3 resulted in a reduction in mean FTH and improvement in BCVA in the ranibizumab group. More extensive focal/grid laser therapy in the other 2 groups may have reduced the need for more frequent ranibizumab injections to control edema. Application to Clinical Practice: Long-term visual outcomes for treatment of diabetic macular edema with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision.

Original languageEnglish (US)
Pages (from-to)139-145
Number of pages7
JournalJAMA Ophthalmology
Volume131
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Edema
Lasers
Visual Acuity
Therapeutics
Injections
Ranibizumab
Macular Edema
Laser Therapy
Randomized Controlled Trials
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Do, D. V., Nguyen, Q. D., Khwaja, A. A., Channa, R., Sepah, Y. J., Sophie, R., ... Campochiaro, P. A. (2013). Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology, 131(2), 139-145. https://doi.org/10.1001/2013.jamaophthalmol.91

Ranibizumab for edema of the macula in diabetes study : 3-year outcomes and the need for prolonged frequent treatment. / Do, Diana V.; Nguyen, Quan D.; Khwaja, Afsheen A.; Channa, Roomasa; Sepah, Yasir J.; Sophie, Raafay; Hafiz, Gulnar; Campochiaro, Peter A.

In: JAMA Ophthalmology, Vol. 131, No. 2, 01.02.2013, p. 139-145.

Research output: Contribution to journalArticle

Do, DV, Nguyen, QD, Khwaja, AA, Channa, R, Sepah, YJ, Sophie, R, Hafiz, G & Campochiaro, PA 2013, 'Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment', JAMA Ophthalmology, vol. 131, no. 2, pp. 139-145. https://doi.org/10.1001/2013.jamaophthalmol.91
Do, Diana V. ; Nguyen, Quan D. ; Khwaja, Afsheen A. ; Channa, Roomasa ; Sepah, Yasir J. ; Sophie, Raafay ; Hafiz, Gulnar ; Campochiaro, Peter A. / Ranibizumab for edema of the macula in diabetes study : 3-year outcomes and the need for prolonged frequent treatment. In: JAMA Ophthalmology. 2013 ; Vol. 131, No. 2. pp. 139-145.
@article{769bd43f930a46598d96764b80195b0e,
title = "Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment",
abstract = "Objective: To assess the benefit of increased follow-up and treatment with ranibizumab between months 24 and 36 in the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study. Design: Prospective, interventional, multicenter follow-up of a randomized clinical trial. Methods: Patients who agreed to participate between months 24 and 36 (ranibizumab, 28 patients; laser, 22; and ranibizumab + laser, 24) returned monthly and received ranibizumab, 0.5 mg, if foveal thickness (FTH, center subfield thickness) was 250 μm or greater. Main outcome measures were improvement in best-corrected visual acuity (BCVA) and reduction in FTH between months 24 and 36. Results: Mean improvement from the baseline BCVA in the ranibizumab group was 10.3 letters at month 36 vs 7.2 letters at month 24 (ΔBCVA letters = 3.1, P = .009), and FTH at month 36 was 282 μm vs 352 μm at month 24 (ΔFTH=70 μm, P=.006). Changes in BCVA and FTH in the laser group (-1.6 letters and -36 μm, respectively) and the ranibizumab + laser group (+ 2.0 letters and -24 μm) were not statistically significant. The mean number of ranibizumab injections was significantly greater in the ranibizumab group compared with the laser group (5.4 vs 2.3 injections, P = .008) but not compared with the ranibizumab + laser group (3.3, P =.11). Conclusions: More aggressive treatment with ranibizumab during year 3 resulted in a reduction in mean FTH and improvement in BCVA in the ranibizumab group. More extensive focal/grid laser therapy in the other 2 groups may have reduced the need for more frequent ranibizumab injections to control edema. Application to Clinical Practice: Long-term visual outcomes for treatment of diabetic macular edema with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision.",
author = "Do, {Diana V.} and Nguyen, {Quan D.} and Khwaja, {Afsheen A.} and Roomasa Channa and Sepah, {Yasir J.} and Raafay Sophie and Gulnar Hafiz and Campochiaro, {Peter A.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1001/2013.jamaophthalmol.91",
language = "English (US)",
volume = "131",
pages = "139--145",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Ranibizumab for edema of the macula in diabetes study

T2 - 3-year outcomes and the need for prolonged frequent treatment

AU - Do, Diana V.

AU - Nguyen, Quan D.

AU - Khwaja, Afsheen A.

AU - Channa, Roomasa

AU - Sepah, Yasir J.

AU - Sophie, Raafay

AU - Hafiz, Gulnar

AU - Campochiaro, Peter A.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Objective: To assess the benefit of increased follow-up and treatment with ranibizumab between months 24 and 36 in the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study. Design: Prospective, interventional, multicenter follow-up of a randomized clinical trial. Methods: Patients who agreed to participate between months 24 and 36 (ranibizumab, 28 patients; laser, 22; and ranibizumab + laser, 24) returned monthly and received ranibizumab, 0.5 mg, if foveal thickness (FTH, center subfield thickness) was 250 μm or greater. Main outcome measures were improvement in best-corrected visual acuity (BCVA) and reduction in FTH between months 24 and 36. Results: Mean improvement from the baseline BCVA in the ranibizumab group was 10.3 letters at month 36 vs 7.2 letters at month 24 (ΔBCVA letters = 3.1, P = .009), and FTH at month 36 was 282 μm vs 352 μm at month 24 (ΔFTH=70 μm, P=.006). Changes in BCVA and FTH in the laser group (-1.6 letters and -36 μm, respectively) and the ranibizumab + laser group (+ 2.0 letters and -24 μm) were not statistically significant. The mean number of ranibizumab injections was significantly greater in the ranibizumab group compared with the laser group (5.4 vs 2.3 injections, P = .008) but not compared with the ranibizumab + laser group (3.3, P =.11). Conclusions: More aggressive treatment with ranibizumab during year 3 resulted in a reduction in mean FTH and improvement in BCVA in the ranibizumab group. More extensive focal/grid laser therapy in the other 2 groups may have reduced the need for more frequent ranibizumab injections to control edema. Application to Clinical Practice: Long-term visual outcomes for treatment of diabetic macular edema with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision.

AB - Objective: To assess the benefit of increased follow-up and treatment with ranibizumab between months 24 and 36 in the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study. Design: Prospective, interventional, multicenter follow-up of a randomized clinical trial. Methods: Patients who agreed to participate between months 24 and 36 (ranibizumab, 28 patients; laser, 22; and ranibizumab + laser, 24) returned monthly and received ranibizumab, 0.5 mg, if foveal thickness (FTH, center subfield thickness) was 250 μm or greater. Main outcome measures were improvement in best-corrected visual acuity (BCVA) and reduction in FTH between months 24 and 36. Results: Mean improvement from the baseline BCVA in the ranibizumab group was 10.3 letters at month 36 vs 7.2 letters at month 24 (ΔBCVA letters = 3.1, P = .009), and FTH at month 36 was 282 μm vs 352 μm at month 24 (ΔFTH=70 μm, P=.006). Changes in BCVA and FTH in the laser group (-1.6 letters and -36 μm, respectively) and the ranibizumab + laser group (+ 2.0 letters and -24 μm) were not statistically significant. The mean number of ranibizumab injections was significantly greater in the ranibizumab group compared with the laser group (5.4 vs 2.3 injections, P = .008) but not compared with the ranibizumab + laser group (3.3, P =.11). Conclusions: More aggressive treatment with ranibizumab during year 3 resulted in a reduction in mean FTH and improvement in BCVA in the ranibizumab group. More extensive focal/grid laser therapy in the other 2 groups may have reduced the need for more frequent ranibizumab injections to control edema. Application to Clinical Practice: Long-term visual outcomes for treatment of diabetic macular edema with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision.

UR - http://www.scopus.com/inward/record.url?scp=84874080959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874080959&partnerID=8YFLogxK

U2 - 10.1001/2013.jamaophthalmol.91

DO - 10.1001/2013.jamaophthalmol.91

M3 - Article

C2 - 23544200

AN - SCOPUS:84874080959

VL - 131

SP - 139

EP - 145

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 2

ER -